Some children suffer from learning disabilities and experience difficulties in daily life due to poor eye movement, which makes it difficult to read and to play sports. We are developing an evidence-based system that uses eye tracking and eye movement indexing technologies to assess eye movements and provide training for children who are encountering these eyesight challenges. We are currently deploying this system in municipal consultation centers, elementary schools, and after-school day care centers.
Luxana Biotech is a preclinical antisense oligonucleotide (ASO) development company based on proprietary nucleic acids with unique cross-linking structures. We have created the LuxiAP™ ASO drug discovery platform for the central nervous system and ophthalmic fields. The company has collaborative research agreements with multiple pharmaceutical companies and maintains its own ASO pipeline. We are seeking to expand partnership opportunities not only for collaborative research with pharmaceutical companies but also for joint development utilizing our proprietary pipeline.
We are developing technology to produce chemicals through microbial fermentation using renewable biomass resources as feedstock. Primarily targeting the apparel industry, we manufacture dyes and fiber raw materials via microbial fermentation, thereby contributing to reducing environmental impact. Additionally, we are actively pursuing new technological developments beyond microbial fermentation, aiming to supply environmentally conscious materials to the apparel industry by leveraging various technologies.
We are conducting clinical development of an oral therapeutic cancer vaccine. We have completed a Phase I clinical trial targeting urothelial carcinoma and are currently conducting a Phase I/IIa clinical trial for malignant pleural mesothelioma.
We develop and sell therapeutic drugs and skin care cosmetics, focusing on drug transdermal absorption technology that can absorb both water-soluble and hydrophobic compounds of large molecular weight. In particular, in joint research with Kobe University, we found that carbon dioxide transdermal absorption has an increase and activation effect on mitochondria, and it has been revealed that it can safely increase muscle strength, promote healing of wounds/fractures, and inhibit scarring, partial weight loss by promoting fat metabolism, and induce apoptosis in cancer cells. Some products are on the market not only in Japan but also in other countries.
